Evaluation of Electromechanical Endocardial Mapping for Assessment of Myocardial Ischemia and Viability
FDG
+ NH(3)
Enfermedades Cardiovasculares
+ Enfermedades del Corazón
+ Enfermedades Vasculares
Estudio de Tratamiento
Resumen
Fecha de inicio: 1 de agosto de 1999
Fecha en la que se inscribió al primer participante.A novel left ventricular (LV) mapping system (Biosense, Inc.) uses low-intensity magnetic field energy to determine the location of sensor-tipped catheter electrodes within the LV. On the basis of previous experimental and human studies correlating the extent of myocardial ischemia with the amplitude of electrical signals, we hypothesize that such an integrated LV electromechanical mapping system could be used to distinguish healthy from ischemic or immobile myocardium on the basis of the extent of electromechanical endocardial signals. If this hypothesis is confirmed, the ability to detect on-line myocardial viability and ischemia in the catheterization laboratory may be feasible. The present study attempts to distinguish between ischemic, immobile, and normal myocardium by comparing LV electromechanical mapping data at rest and during pharmacologic stimulation, with imaging studies using MRI, PET, thallium and echo in patients with coronary artery disease.
Protocolo
Esta sección proporciona detalles del plan del estudio, incluyendo cómo está diseñado y qué se está evaluando.Se reclutarán 71 pacientes
Número total de participantes que el ensayo clínico espera reclutar.Estudio de Tratamiento
Elegibilidad
Los investigadores buscan pacientes que cumplan ciertos criterios, conocidos como criterios de elegibilidad: estado general de salud o tratamientos previos.Cualquier sexo
Sexo biológico de los participantes elegibles para inscribirse.Voluntarios sanos no permitidos
Indica si personas sanas, sin la condición que se estudia, pueden participar.Condiciones
Patología
Criterios
Male or female patients greater than or equal to 21 years undergoing diagnostic cardiac catheterization. Must not have unstable angina. No significant unprotected left main disease (greater than 50% stenosis). No recent myocardial infarction (less than 4 weeks). Females must not be pregnant or lactating. No chronic atrial fibrillation. No prosthetic heart valves. No significant aortic valve pathology (sclerosis or stenosis) which might prevent retrograde crossing of catheter across the aortic valve. No left ventricular thrombus seen on echo. No severe heart failure (NYHA Class 4). No severe ectopy (greater than 1 every 10 beats) or ventricular tachycardia. No active infections (fever and elevated white cell count). Patients will not be considered for this protocol because of contraindications to MRI scan, as stated below: Pacemaker Implanted defibrillator Cerebral aneurysm clips Swan Ganz catheter with electrodes for a thermistor Cochlear implants Insulin pumps Neural stimulator
Centros del Estudio
Estos son los hospitales, clínicas o centros de investigación donde se lleva a cabo el estudio. Puedes encontrar la ubicación más cercana a ti y su estado de reclutamiento.Este estudio tiene una ubicación
National Heart, Lung and Blood Institute (NHLBI)
Bethesda, United StatesAbrir National Heart, Lung and Blood Institute (NHLBI) en Google Maps